

Company News

August 26, 2002

Public Relations
Ono Pharmaceutical Co., Ltd.
Tel: +81-6-6222-5551
Fax: +81-6-6222-2875

Schering-Plough launched Leukotriene Antagonist Pranlukast in Mexico

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City) announces that Schering-Plough International, the worldwide pharmaceutical operations of Schering-Plough Corporation of Kenilworth, New Jersey, USA, launched pranlukast capsule (Latin American trademark: Azlaire) for bronchial asthma and allergic rhinitis on July 24, 2002 in Mexico.

Schering-Plough holds an exclusive license to develop and market pranlukast in Latin America (Japanese trademark: Onon[®] Capsule and Onon[®] Dry Syrup) under the agreement signed in November 2000. Schering-Plough has been proceeding with the submission of new drug applications in Latin American countries, and has already obtained approvals on the capsule product in 9 countries including Mexico, Argentina and Venezuela, and on the dry syrup product in 7 countries.

Both capsule and dry syrup products are expected to be launched in the above approved countries.

Ono is responsible for manufacturing and supply of intermediate products and will receive milestone payments upon achievement of targeted product sales.

Reference

The countries in which pranlukast products (capsule and dry syrup) are approved (as of August 20, 2002)

- * The countries in which pranlukast capsule is approved (9 countries)
Mexico, Argentina, Venezuela, Guatemala, Colombia, Dominican Republic, Costa Rica, Panama and Honduras
- * The countries in which pranlukast dry syrup is approved (7 countries)
Mexico, Argentina, Venezuela, Guatemala, Colombia, Dominican Republic and El Salvador
- * The countries under submission of new drug applications (5 countries)
Brazil, Chile, Nicaragua, Ecuador and Peru

Pranlukast capsule is indicated for the treatment of bronchial asthma and allergic rhinitis.
Pranlukast dry syrup is indicated for pediatric bronchial asthma.